Vaccines Europe calls for an European Influenza Day

Posted by: on Apr 29, 2015 | No Comments

Luxembourg, April 30th, 2015 – Vaccines Europe launch a call on the European Commission and Member States to align and streamline communications activities around the seasonal influenza vaccination campaigns by setting a European Influenza Day to launch seasonal vaccination every year.

Vaccines Europe President Andrea Rappagliosi prompts the establishment of a common EU-wide day to launch the seasonal influenza vaccination
campaigns across all Member States in occasion of the DG SANTÉ High-Level Hearing on Seasonal Influenza Vaccination.

The meeting, organised by the European Commission back-to-back to the Workshop on joint procurement being held in Luxembourg on 29-30 April 2015, is bringing together key stakeholders across public health, regulatory, industry and civil society to discuss concrete measures that can increase flu vaccination rates in the EU.

Andrea Rappagliosi said that “the establishment of a common date to kick-off the Member States communication campaigns with a single voice and in an aligned manner will significantly raise awareness on the needs and means to keep populations properly immunised against flu”.

Communications on the benefits of flu vaccination came on the spotlight as one of the crucial factors that must be properly addressed at EU level to help achieving the necessary coverage targets, according to the Commission Staff Working Document following up on the implementation of 2009 Council Recommendation on Seasonal Influenza Vaccination.

Seasonal flu epidemics still represent an underestimated cause of significant morbidity and mortality in the EU; ECDC estimates up to 40,000 premature deaths on an average influenza season. Despite recommendations for vaccination being in place across most EU countries, the gap with actual implementation stays large with only two EU Member States reaching the
Council Recommendation’s 75% target. Political leadership remains key to addressing the status quo.

#Ends#

About Vaccines Europe
Vaccines Europe is the specialised vaccine group operating within the
European Federation of Pharmaceutical Industries and Associations (EFPIA).
It represents the major research-based vaccine companies as well as small
and medium-sized enterprises operating in Europe.
For more information on Vaccines Europe, visit www.vaccineseurope.eu
For more information on EFPIA, visit www.efpia.eu

Download a version of this press release

Media contacts
Any media queries can be addressed to
Magdalena R. de Azero
Executive Director, Vaccines Europe
+ 32.2.626.25.43
magdalena.deazero@vaccineseurope.eu

Sanofi Pasteur MSD welcomes the 10 year Anniversary of European Immunization Week 2015

Posted by: on Apr 20, 2015 | No Comments

European vaccine leader hosts events across the region to help raise awareness of immunization throughout life

Lyon, France – April 20, 2015 – Sanofi Pasteur MSD welcomes the World Health Organization’s European Immunization Week 2015 (EIW 2015) with a series of awareness-raising events across the region, taking place between April 20th and 25th. Sanofi Pasteur MSD, a European leader for vaccines in Europe, has joined forces with NGOs and healthcare professionals to help raise awareness of the important benefits of full vaccination throughout life.

This year, the European Immunization Week celebrates its 10 year anniversary and focuses on the need for renewed commitment to immunization. Communication and advocacy activities will particularly focus on elimination of measles and rubella, maintaining the Region’s polio-free status, and the introduction of new vaccines.

“Vaccines are widely recognised as one of the most cost-effective healthcare investments and we must collectively respond to close the immunisation gap in Europe”, said Dr Jean-Paul Kress, President of Sanofi Pasteur MSD. “We are strongly committed to take part of life long immunisation efforts for the benefit of Europeans at all ages”, he also noted.

“Despite the availability of a safe and effective vaccine in use for 50 years, measles remains one of the leading causes of death and disabilities among young children, said Dr. Jean-Paul Kress, “We believe that public & private actors have to work together to ensure that no one should suffer any longer from a vaccine preventable disease”, he concluded.

During the European Immunization Week 2015 all Sanofi Pasteur MSD subsidiaries and the Headquarter Office will engage with stakeholders, scientific societies and citizens through a series of events to set immunization at the center of the European health agenda.

For further information about events across Europe, visit the WHO’s dedicated campaign website: http://eiw.euro.who.int. European Immunization Week 2015 will coincide with the global World Immunization Week (WIW) campaign spearheaded by WHO headquarters. This year’s campaign focuses on closing the immunization gap and reaching equity in immunization levels as outlined in the Global Vaccine Action Plan (GVAP).

# # #

CO01213
About European Immunization Week www.eiw.euro.who.int
European Immunization Week (EIW) promotes the core message that the immunization of every child is vital to prevent diseases and protect life. The goal is to increase vaccination coverage by raising awareness of the importance of immunization. “Renewed commitment to immunization” will be the theme of the 10th anniversary of the EIW 2015 which will be celebrated on 20–25 April.
About Sanofi Pasteur MSD www.spmsd.com
Sanofi Pasteur MSD is a European joint venture formed between Sanofi Pasteur (the vaccine division of Sanofi) and Merck (known as MSD outside the United States and Canada). Combining innovation and expertise, Sanofi Pasteur MSD is the only European pharmaceutical company dedicated exclusively to the distribution of vaccines. Sanofi Pasteur MSD makes use of the combined expertise resulting from Sanofi Pasteur and Merck’s research to focus on the development of new vaccines in Europe in order to produce the most effective, most acceptable and better tolerated vaccines.
– END –

Download a version of this press release

Contact:
Sanofi Pasteur MSD
Sylvia Martin-Jarrand
Tel : +33 4 37 28 40 55
Mob : +33 6 33 46 13 65
smartin-jarrand@spmsd.com

Sanofi Pasteur MSD recognized as one of the Best Places to Work in Spain

Posted by: on Jun 17, 2014 | No Comments

Spanish affiliate named one of the top companies with 50 – 100 employees

 Lyon, May 12th, 2014 – We’re pleased to share the news that on May 7th, our Spanish affiliate was recognized by the Great Place to Work organisation as one of the 50 Best Places to Work in Spain in 2014.

Our team was recognized among 11 other pharmaceutical companies on the list and captured a spot among the top 8 best companies with 50 – 100 employees.

“I believe our business model provides a key strategic advantage.  We are able to work closely all together, proactively build trust and pride amongst each other,” notes Ricardo Brage, Vice President of Sanofi Pasteur MSD and Managing Director of the company in Spain.  “It contributes to a strongly positive work environment here.”

“This award publicly confirms a trend we’ve seen with our Spanish team over the last several years: strong performance clearly achieved through exceptional teamwork,” adds Jean-Paul Kress, President of Sanofi Pasteur MSD.

Sanofi Pasteur MSD joins the Great Place to Work organisation in congratulating our team and all of the award winners in 2014.  We’re proud to represent vaccine companies in this leading group of organisations across Europe.

For more information on the Great Place to Work organisation, visit http://www.greatplacetowork.com/index.php

# # # 

About Sanofi Pasteur MSD www.spmsd.com

Sanofi Pasteur MSD is a European joint venture formed between Sanofi Pasteur (the vaccine division of Sanofi) and Merck (known as MSD outside the United States and Canada). Combining innovation and expertise, Sanofi Pasteur MSD is the only European pharmaceutical company dedicated exclusively to the distribution of vaccines. Sanofi Pasteur MSD makes use of the combined expertise resulting from Sanofi Pasteur and Merck’s research to focus on the development of new vaccines in Europe in order to produce the most effective, most acceptable and better tolerated vaccines.

– END –

For further information please contact:

Sanofi Pasteur MSD Corporate
Sylvia Martin-Jarrand
Tel : +33 4 37 28 40 55
Mob : +33 6 74 85 19 63
smartin-jarrand@spmsd.com

Sanofi Pasteur MSD Spain
Cristina Justo
Tel : + 34 91 371 78 04
cjusto@spmsd.com

Download a copy of the the full release here.